Tax Season is Here! Save 15% on H&R Block Online
iconAll times are GMT -4. The time now is 01:31 PM. | Search:

» StockRants Stock Forum » Public Stock Forums » US Stock Picks » Strong Buy: (TRVI) MC $49 M--Cash $53 M--Phase 3 data soon =500%+Upside

Thread Tools Search this Thread
Old 05-28-2020, 09:18 AM   Nav to Top  #1
Senior Trader
Biohero's Avatar
Join Date: Jan 2012
Location: Frankfurt
Posts: 305
Favorites: Aapl celg onxx
Rep Power: 118
Reputation: 36
Biohero is on a distinguished road
Default (TRVI) MC $49 M--Cash $53 M--Phase 3 data soon =500%+Upside

Here is an extremely underpriced (trading under cash) and undiscovered biotech stock :

(TRVI-DD) Market Cap $49 million / Cash $53 Million or Cash untill Q4 2021 /Phase 3 Drug targeting Prurigo Nodularis with NO approved treatment for this indication to date a potential Blockbuster .Company has only 17.8 million outstanding shares almost all shares held by Insiders & institutional investors (see below) .This MASSIVE underpriced extreme low float stock could hit $20+ on positive Phase 3 readout and more with FDA approval .GL

Trevi Therapeutics (TRVI)

Market Cap: $49 Million
Cash: $53 Míllion (or untill Q4 2021)
Price: $2.79

Shares Out: 17.8 Million

Company Presentation

Major Shsareholders:

TPG Capital, L.P...6.3M
New Enterprise ...5.9M
Omega Fund ...1.3M
Lundbeckfond ...1.2M
Fidelity ...792.7K
Franklin ...587.3K
Richard King ...347.2K
Meeker (David P)...311.8K
Good (Jennifer L)...206.2K
Sciascia (Thomas R)...193.7K

BMO Capital Markets analyst Gary Nachman initiated coverage of shares of Trevi with an Outperform rating and $15 price target.

The Thesis

Trevi's key product Nalbuphine ER has a solid track record and substantial evidence supporting its mechanism of treating various chronic pruritus and cough conditions, analyst Nachman said in a Monday morning note.

Nalbuphine ER is an oral formulation of Nalbuphine, an injectable in use for decades to treat pain, and it is the only opioid-based pain drug not scheduled by the DEA, the analyst added.

The pipeline asset has shown positive clinical data in a large Phase 2b/3 trial in uremic pruritus associated with chronic kidney disease, and in a smaller Phase 2 study in prurigo nodularis, the lead indication, the asset achieved statistical significance in a post-hoc analysis for patients who completed the study on the higher dose, Nachman noted.

The analyst said prurigo nodularis is an area of high unmet need with a sizeable market opportunity.

A larger Phase 2b/3 study for the lead indication for which enrollment has begun, according to the analyst, has a good chance of success. Data from the study is expected in the first half of 2020, he added.

"We see a compelling valuation at current levels after recent IPO, with further optionality for Nalbuphine ER in additional indications beyond PN," BMO concluded.

Biohero is offline   Rate this post Yes | No Reply With Quote

Similar Threads
Thread Thread Starter Forum Replies Last Post
Strong Buy: MDWD =MC $75 M- Cash $33 M - Attractive Pipeline with huge Upside Biohero US Stock Picks 0 12-09-2019 11:51 AM
Strong Buy: VRNA =MC $57 M-- Cash $51 M --COPD Phase 2b data this month Biohero US Stock Picks 0 12-04-2019 08:37 AM
Strong Buy: CTX.TO (MC $9 M) Trading at Cash + 5x Marketed Products = Huge Upside Biohero Canadian Stock Picks 0 01-30-2018 11:24 AM
Strong Buy: TNXP (MC $32M) (Cash $34M) O/S 7.5 M / Phase 3 Data in 1H 2018 =More than just cheap Biohero US Stock Picks 6 01-23-2018 04:48 AM
Any data out there on what percentage of drugs past phase III get FDA approval? Billy Traders Lounge 1 05-30-2009 07:40 PM

Thread Tools Search this Thread
Search this Thread:

Advanced Search

Posting Rules
You may not post new threads
You may not post replies
You may not post attachments
You may not edit your posts

BB code is On
Smilies are On
[IMG] code is On
HTML code is On